CD274 and non-small cell lung carcinoma: In the CITYSCAPE trial, comparable PFS improvement with tiragolumab plus atezolizumab relative to atezolizumab monotherapy was seen in PD-L1–high NSCLC patients (PFS hazard ratio (HR) 0.23, 95% CI: 0.10–0.53).55